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Nodal Stations and Diagnostic Performances of Endobronchial 
Ultrasound-Guided Transbronchial Needle Aspiration in Patients 
with Non-Small Cell Lung Cancer
There are no accurate data on the relationship between nodal station and diagnostic 
performance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA). We evaluated the impact of nodal station and size on the diagnostic performance 
of EBUS-TBNA in patients with non-small cell lung cancer (NSCLC). Consecutive patients 
who underwent EBUS-TBNA of mediastinal or hilar lymph nodes for staging or diagnosis of 
NSCLC were included in this retrospective study. Between May 2009 and February 2010, 
EBUS-TBNA was performed in 373 mediastinal and hilar lymph nodes in 151 patients. The 
overall diagnostic sensitivity, specificity, accuracy and negative predictive value (NPV) of 
EBUS-TBNA were 91.6%, 98.6%, 93.8%, and 84.3%, respectively. NPV of the left side 
nodal group was significantly lower than those of the other groups (P = 0.047) and 
sensitivity of the left side nodal group tended to decrease (P = 0.096) compared with those 
of the other groups. Diagnostic sensitivity and NPV of 4L lymph node were 83.3% and 
66.7%, respectively. However, diagnostic performances of EBUS-TBNA did not differ 
according to nodal size. Bronchoscopists should consider the impact of nodal stations on 
diagnostic performances of EBUS-TBNA.
Key Words: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration; Lymph 
Nodes; Mediastinum; Non-Small Cell Lung Cancer
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Nodal metastasis is the most important prognostic factor in pa-
tients with non-small cell lung cancer (NSCLC) and affects ther-
apeutic strategies (1, 2). Median survival decreases progressive-
ly as nodal metastasis increases (3). Although radiological mo-
dalities such as computed tomography (CT) scan or integrated 
positron emission tomography (PET)/CT scan provide signifi-
cant information, radiographic staging alone does not ensure 
accurate nodal staging in NSCLC patients because of its relatively 
low sensitivity and specificity (4). Thus, all candidates for cura-
tive surgical treatment require histopathological assessment of 
nodal involvement (5, 6). Although mediastinoscopy has been 
the gold standard for nodal staging, it is an invasive technique, 
requires general anesthesia, has a morbidity of 2%, and has a 
mortality of 0.08% (5).
  Recently, EBUS-TBNA was introduced as a minimally inva-
sive technique for nodal staging and many previous studies have 
shown that EBUS-TBNA affords excellent diagnostic performance 
with a sensitivity of 69%-99.1% and NPV of 11%-98.9% (7-9). Ad-
ditionally, it allows for access to the hilar and interlobar lymph 
nodes, which are inaccessible with mediastinoscopy (10). How-
ever, despite these advantages, some authors have indicated 
that EBUS-TBNA has a relatively high false negative rate com-
pared with mediastinoscopy and have claimed that mediasti-
noscopy is still required as a gold standard (11, 12).
  Studies have been performed on the factors associated with 
the diagnostic performance of EBUS-TBNA and have suggested 
an association between nodal station and diagnostic perfor-
mance (12-14). However, there are no accurate data on the re-
lationship between nodal station and diagnostic performance 
and other factors affecting diagnostic performance. Thus, the 
aim of this study was to evaluate the overall diagnostic perfor-
mance and impact of nodal station and nodal size as influenc-
ing factors on the diagnostic performance of EBUS-TBNA for 
nodal staging in NSCLC patients.
MATERIALS AND METHODS
Study patients and design
In this retrospective study, records were reviewed for all patients 
who underwent EBUS-TBNA of mediastinal and hilar lymph Jhun BW, et al.  •  Diagnostic Performance of EBUS-TBNA
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nodes for diagnosis or staging of NSCLC at the Samsung Medi-
cal Center, between May 2009 and February 2010. All patients 
underwent a conventional diagnostic work up, consisting of a 
physical examination, laboratory investigations, chest X-ray, 
sputum cytology, and transthoracic fine-needle aspiration in 
cases of peripheral lung lesions. Chest CT and integrated PET/
CT scans were conducted in all patients prior to EBUS-TBNA. 
EBUS-TBNA was performed for nodal staging in patients with 
pathologically confirmed NSCLC, and for diagnosis and nodal 
staging in patients with radiologically suspicious NSCLC.
  All patients in whom nodal metastases were detected by 
EBUS-TBNA underwent multimodality treatment, chemother-
apy, radiation or best supportive care considering disease stage, 
performance status, and age. If both benign and malignant re-
sults were revealed by EBUS-TBNA among the patients who 
underwent EBUS-TBNA for multiple lymph nodes, all negative 
results of lymph node(s) by EBUS-TBNA were not immediately 
confirmed by mediastinoscopy or lymph node dissection since 
treatments could be determined based on malignant results of 
lymph nodes. If only benign results were revealed by EBUS-TB-
NA among the patients who underwent EBUS-TBNA for multi-
ple lymph nodes, negative result of mediastinal lymph nodes 
was confirmed by mediastinoscopy or lymph node dissection. 
Lymph nodes that had benign EBUS-TBNA results but that were 
not confirmed by surgical sampling and lymph nodes that had 
non-diagnostic EBUS-TBNA results were excluded from diag-
nostic performances analysis.
  All lymph nodes that included analysis were categorized into 
several groups according to nodal station as proposed by the 
IASCL lymph node map (15), and nodal size.
Integrated PET/CT scan
After fasting for at least 6 hr before PET/CT examination, the pa-
tients received an intravenous injection of 370 MBq of 
18F-FDG 
and then rested for 45 min before undergoing imaging. Image 
acquisition was performed using an integrated PET/CT device 
(Discovery LS, GE Healthcare, Milwaukee, WI, USA) that consist-
ed of an Advance NXi PET scanner and an 8-slice Light Speed 
Plus CT scanner. Lymph nodes were classified as positive on 
18F-FDG PET/CT if mediastinal and hilar lymph nodes had in-
creased 
18F-FDG uptake compared with the background activi-
ty of the surrounding mediastinal or lung tissues.
EBUS-TBNA
The indications for EBUS-TBNA for mediastinal and hilar lymph 
nodes were 1) the presence of mediastinal or hilar lymph node 
with a short axis diameter of  ≥ 10 mm on chest CT or 2) medias-
tinal or hilar lymph node with increased FDG uptake compared 
with surrounding tissue on PET/CT scan regardless of size.
  EBUS-TBNA was performed using a flexible ultrasonic punc-
ture bronchoscope with a linear scanning transducer (BF-UC-
260F-OL8, Olympus, Tokyo, Japan). TBNA biopsies were per-
formed using a dedicated 22-gauge needle (NA-201SX-4022, 
Olympus). All procedures were performed under conscious seda-
tion using midazolam. Local anesthesia was achieved by nebuli-
zation with 4% lidocaine. An examination of all mediastinal and 
hilar node stations accessible by EBUS was performed before 
TBNA procedure. If more than one node was detected, EBUS-
TBNA was performed at all accessible node stations. N3 nodes 
were sampled first, and then N2, and N1 nodes were sampled. 
We attempted at least three passes at each node as possible. When 
tissue core was obtained, we attempted at least two passes as 
possible (16). All aspirate specimens were expelled onto glass 
slides, smeared, fixed immediately, and sent for cytological and/ 
or histological examination. Rapid on-site cytopathologic eval-
uation (ROSE) was not performed, and all procedures were per-
formed by two bronchoscopists.
Pathological results and diagnostic standards
All aspirate samples were categorized by pathological report. 
The presence of frank malignant cells or rare cells suspicious for 
malignancy was considered malignant. The presence of no tu-
mor cells in a background of lymphoid tissue was considered 
benign. Samples that showed only blood, mucus, benign bron-
chial epithelial cells or no lymphoid tissue were considered non-
diagnostic and inadequate. All specimens were evaluated by an 
experienced lung pathologist.
  Lymph nodes identified as malignant by EBUS-TBNA or sur-
gical sampling were considered positive result. Lymph nodes 
identified as benign by EBUS-TBNA and by surgical sampling 
were accepted as true negatives.
Statistical method
All data are presented as median (range) or number (%). The 
sensitivity, specificity, diagnostic accuracy and negative predic-
tive value (NPV) of EBUS-TBNA and PET/CT were calculated 
using the standard definitions. The overall diagnostic perfor-
mance of EBUS-TBNA and the difference in diagnostic perfor-
mance in relation to each nodal station and size were evaluated 
on a per-nodal station basis. Differences in diagnostic perfor-
mance in relation to nodal station and size were evaluated with 
the chi-square test or Fisher’s exact test; P values of  < 0.05 were 
considered to indicate statistical significance. All statistical anal-
yses were performed using the PASW Statistics 18 software.
Ethics statement
This study was approved by the institutional review board of the 
Samsung Medical Center (IRB No. 2010-11-004). The require-
ment for informed consent from the individual patients was 
waived because of the retrospective nature of the study.Jhun BW, et al.  •  Diagnostic Performance of EBUS-TBNA
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RESULTS
EBUS-TBNA was performed in 373 mediastinal and hilar lymph 
nodes of 151 patients with NSCLC between May 2009 and Feb-
ruary 2010. Characteristics of the 151 study patients are shown 
in Table 1. The median age of these patients was 65 yr, and 117 
were men. Adenocarcinoma and squamous cell carcinoma ac-
counted for approximately 90%. Among the 151 patients, EBUS-
TBNA detected nodal metastases in 83 patients (1 was revealed 
as false positive). During the study period, there was no serious 
complication.
  Fig. 1 shows the results of lymph nodes sampled by EBUS-
TBNA. Of the total of 373 nodes, 143 were identified as malig-
nant by EBUS-TBNA. Exceptionally, two (station 4R, 7) of 143 
nodes subsequently underwent surgical sampling, because only 
small malignant foci were detected on pathological reports. One 
(4R) of the two nodes was revealed as malignant, but the other 
(station 7) was revealed as benign and accepted as a false posi-
tive result. Of the 222 nodes that were benign by EBUS-TBNA, 
83 subsequently underwent surgical sampling, 70 of these 83 
nodes were revealed as benign, and 13 were revealed as malig-
nant. However, 139 nodes that had benign EBUS-TBNA results 
but that were not confirmed by surgical sampling and 8 nodes 
that had non-diagnostic EBUS-TBNA results were excluded from 
diagnostic performances analysis. Two non-diagnostic results 
False 
negative 
n = 13
False 
positive 
n = 1
True 
negative 
n = 70
True 
positive 
n = 142
No 
n = 6
Yes 
n = 2
Benign 
n = 2
No 
n = 139
Neo-adjuvant chemotherapy (n = 38) 
Definitive CCRT (n = 9) 
Radiotherapy (n = 27) 
Chemotherapy (n = 12) 
Supportive management (n = 53)
Malignant by EBUS-TBNA 
n = 143
LNs sampled by EBUS-TBNA 
n = 373
Benign by EBUS-TBNA 
n = 222
Mediastinoscopy or 
systematic LN dissection
Yes 
n = 83
Mediastinoscopy or 
systematic LN dissection 
n = 2
Non-diagnostic by EBUS-TBNA 
n = 8
Mediastinoscopy or 
systematic LN dissection
Fig. 1. Results of lymph nodes sampled by EBUS-TBNA. LN, lymph node; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; CCRT, concurrent 
chemoradiotherapy.
Table 1. Characteristics of subjected patients
Characteristics No. (%) or median (range)
Total patients 151
Age (yr)   65 (31-82)
Gender (male/female) 117 (77.5%)/34 (22.5%)
Histologic type
   Adenocarcinoma
   Squamous cell carcinoma
   Large cell carcinoma
   NSCLC, unspecified*
 
  65 (43.0%)
  71 (47.0%)
  6 (4.0%)
  9 (6.0%)
Indication for EBUS-TBNA
   Staging
   Diagnosis and staging
 
119 (78.8%)
  32 (21.2%)
Examined lymph nodes per patient 2 (1-7)
Duration of the procedures (min)   35 (18-80)
*NSCLC, unspecified, pleomorphic carcinoma, spindle cell carcinoma; EBUS-EBNA, 
endobronchial ultrasound-guided transbronchial needle aspiration.
Table 2. Characteristics of lymph nodes included in the diagnostic performance anal-
ysis
Characteristics No. (%) or median (range)
Total lymph nodes 226 (100%)
Station
   #1
   #2
   #3P
   #4
   #7
   #10
   #11
 
   2 (0.9%)
 16 (7.1%)
   1 (0.4%)
   97 (43.0%)
   83 (36.7%)
   3 (1.3%)
   24 (10.6%)
Size (mm)
   Short axis diameter
   Long axis diameter
 
11 (4-51)
18 (5-57)
Needle passes per lymph node 2 (1-5)
Acquisition of tissue core  215 (95.1%)
Adequate sample 226 (100%)
#1, low cervical, supraclavicular, and sternal notch nodes; #2, paratracheal nodes; 
#3P, retrotracheal nodes; #4, lower paratracheal nodes; #7, subcarinal nodes; #10, 
hilar nodes; #11, interlobar nodes.Jhun BW, et al.  •  Diagnostic Performance of EBUS-TBNA
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from EBUS-TBNA were confirmed as benign by surgical sam-
pling.
  The characteristics of lymph nodes included in the analysis 
are shown in Table 2. In total, 226 nodes were included in the 
analysis, 196 were subcarinal and paratracheal lymph nodes. A 
total of 215 aspirate samples contained tissue cores. Median size 
of lymph nodes was 11 (4-51) mm and median number of passes 
per lymph node was 2 (1-5).
  The overall diagnostic sensitivity, specificity, accuracy and 
NPV of EBUS-TBNA on a per-nodal basis were 91.6% (95% con-
fidence interval [CI], 86.2%-95.0%), 98.6% (95% CI, 92.4%-99.8%), 
93.8% (95% CI, 89.95%-96.3%) and 84.3% (95% CI, 75.0%-90.6%), 
respectively (Table 3). The diagnostic performances tended to 
decrease in the order of station 7, 4R, 4L, and 11L, especially in 
terms of sensitivity and NPV.
  When all lymph nodes included in the analysis were catego-
rized into a mediastinal node group and hilar/interlobar node 
group, there was no significant difference in diagnostic perfor-
mance between the groups (Table 4). However, when catego-
rized into three nodal groups, - midline (3P and 7), right side 
(1R, 2R, 4R, 10R, and 11R), and left side (4L, 10L, and 11L) -, NPV 
of the left side nodal group was significantly lower than those of 
the other groups (P = 0.047) and sensitivity of the left side nodal 
group tended to decrease (P = 0.096) compared with those of 
the other groups (Table 4).
  To evaluate the effect of nodal size on diagnostic performances, 
all lymph nodes included in the analysis were categorized into 
three groups according to the short axis diameter measured by 
chest CT (Table 5). As the nodal size increased, the extent of met-
astatic involvement increased, and for the nodal size of  ≥ 20 mm 
group, there was no false negative result. However, diagnostic 
performances of EBUS-TBNA did not differ according to nodal 
size (P = 0.0305,  > 0.558). 
  Among 226 lymph nodes which were included in the diag-
nostic performance analyses, PET/CT scans were available for 
225 lymph nodes. The overall diagnostic sensitivity, specificity, 
accuracy and NPV of PET/CT scan on a per-nodal basis were 
72.9% (95% CI, 65.4%-79.3%), 77.1% (95% CI, 66.0%-85.4%), 56.3% 
(95% CI, 46.3%-65.7%) and 74.2% (95% CI, 68.1%-79.5%), respec-
tively.
DISCUSSION
In this study, the overall sensitivity, specificity, accuracy and 
NPV of EBUS-TBNA for nodal staging in NSCLC on a per-nodal 
basis were 91.6%, 98.6%, 93.8%, and 84.3%, respectively, similar 
to those of previous studies showing excellent diagnostic per-
formance (7-9). Diagnostic performances of EBUS-TBNA were 
Table 3. Diagnostic performances of EBUS-TBNA in relation to each nodal station (%)
Station No. Sensitivity Specificity Accuracy NPV
Prevalence 
of metas-
tasis
Total 226 91.6 98.6 93.8 84.3 68.6
#1R 2 100 NA 100 NA 100
#2R 16 100 100 100 100 50.0
#3P 1 100 NA 100 NA 100
#4R 65 91.7 100 92.4 81.0 73.8
#4L 32 83.3 100 87.5 66.7 75.0
#7 83 94.2 96.8 95.2 90.9 62.7
#10R 1 100 NA 100 NA 100
#10L 2 100 NA 100 NA 100
#11R 15 100 100 100 100 73.3
#11L 9 66.7 100 77.8 60 66.7
#1R, right low cervical, supraclavicular, and sternal notch nodes; #2R, right paratra-
cheal nodes; #3P, retrotracheal nodes; #4R/4L, right/left lower paratracheal nodes; 
#7, subcarinal nodes; #10R/10L, right/left hilar nodes; #11R/11L, right/left interlobar 
nodes; NPV, negative predictive value; NA, not available.
Table 4. Diagnostic performances of EBUS-TBNA according to nodal groups (%)
Station Number
Size (mm),  
median (range)
Sensitivity Specificity Accuracy NPV
Prevalence of  
metastasis
Mediastinal
Hilar/Interloar
P value
199
  27
10 (4-51)
14 (8-25)
91.9
90.0
0.676
98.4
100
1
94.0
92.6
0.677
85.1
77.8
0.627
67.8
74.1
Right side
Midline
Left side
P value
  99
  84
  43
12 (5-32)
10 (5-34)
10 (4-51)
94.3
94.3
81.3
0.096
100
96.8
100
1
96.0
95.2
86
0.073
87.9
90.9
64.7
0.047
70.7
63.1
74.4
NPV, negative predictive value.
Table 5. Diagnostic performances of EBUS-TBNA in relation to nodal size 
Short axis diameter Number Sensitivity (%) Specificity (%) Accuracy (%) NPV (%)
Prevalence of  
metastasis
LN size < 10 mm
10 mm ≤ LN size < 20 mm
20 mm ≥ LN size
P value
  86
117
  23
88.1
91.1
100
0.305
97.7
100
NA
1
93.2
93.2
100
0.558
90
77.1
NA
0.140
48.8
76.9
100
NPV, negative predictive value; LN, lymph nodes; NA, not available.Jhun BW, et al.  •  Diagnostic Performance of EBUS-TBNA
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superior to those of PET/CT scan in this study. Interestingly, we 
found relevance between the nodal station and diagnostic per-
formance of EBUS-TBNA. In our study, false negative results 
were identified at station 7 (3 nodes), 4R (4 nodes), 4L (4 nodes), 
and 11L (2 nodes). When all lymph nodes were categorized into 
the three groups, NPV and sensitivity of the left nodal station 
group were lower than those of the other nodal station groups 
(P = 0.047 for NPV and P = 0.096 for sensitivity). Diagnostic sen-
sitivity and NPV of 4L lymph node were 83.3% and 66.7%, respec-
tively. Therefore, our data suggest that negative EBUS-TBNA re-
sults of left paratracheal lymph node should be confirmed by 
other modalities such as EUS-FNA or mediastinoscopy out of 
concern for low NPV.
  An association between nodal station and diagnostic perfor-
mance has been suggested in some previous studies. Szlubows-
ki et al. (14) reported that imaging and biopsy of paratracheal 
nodes, particularly on left side, by EBUS-TBNA were technically 
more difficult in a study that evaluated the efficacy of EBUS-
TBNA for nodal staging in 226 NSCLC patients. They reported 
false negative results at station 4R (3 nodes), 4L (2 nodes), and  
7 (8 nodes), and compared diagnostic performances between 
the subcarinal node group and paratracheal node group. How-
ever, there was no difference in diagnostic performance. Addi-
tionally, Cerfolio et al. (12) reported diagnostic performances 
for nodal staging of NSCLC patients by EBUS-TBNA and EUS-
FNA and concluded that EBUS-TBNA had high false negative 
rates, especially at stations 4R, 4L, and 7. Although these studies 
had some limitations, they suggested that nodal station may af-
fect the diagnostic performance of EBUS-TBNA. The reason is 
probably related to the anatomical structure. For example, nodes 
at station 4L are located very close to the subaortic area and deep 
in the trachea. Thus, visualizing and sampling at station 4L by 
EBUS-TBNA is relatively more difficult than at the others (14). 
Because of these difficulties, several studies have been performed 
to identify additional yield of the combined approach of EBUS-
TBNA and EUS-FNA for nodal staging in NSCLC patients and 
have shown additional benefits (17, 18).
  Generally, lymph nodes with a short axis diameter of  ≥ 10 mm 
on CT are considered abnormal. In our data, however, the ex-
tent of metastatic involvement in the nodal group with a short 
axis diameter of  < 10 mm was 48.8% (42/86), which is a consid-
erable value. Additionally, there was no statistically significant 
difference in diagnostic performance between the differently 
sized nodal groups. These data suggest that nodal size is not an 
important factor affecting diagnostic performance of EBUS-TB-
NA (19). 
  In our study, false negative results were seen in 13 lymph nodes 
from 11 patients, and the false negative rate was only 8.3% (13/ 
155). Generally, false negative results occur at variable rates, and 
even in experienced hands, false negative rates of 15%-20% may 
be seen (20). Perhaps because we obtained tissue core samples 
in 95.1% and at least three aspirations as possible (at least 2 aspi-
rations when a tissue core specimen was obtained) (16) in 81.4% 
(184/226) of all sampled nodes, the false negative rate in our 
study was low.
  We experienced a patient who had discrepant results of sta-
tion 7 from EBUS-TBNA (malignant) and mediastinoscopy (be-
nign). The patient was diagnosed with squamous cell carcinoma 
in the left upper lobe and had high FDG uptake in the medias-
tinal nodes (2R, 4R, 7) on PET/CT. EBUS-TBNA was performed 
in the order of 2R, 4R, and 7 and reported as “suggestive of met-
astatic carcinoma” at station 7 on histology. Because small foci 
of malignancy were observed in this specimen, the patient sub-
sequently underwent mediastinocopy, which revealed benign 
results at stations 7, and 4L. False positive results have been re-
ported in other EBUS-TBNA and EUS-FNA studies (13, 21), but 
were uncommon, an accurate frequency and causes have not 
been reported. Some authors indicated that false positive results 
can occur if TBNA is performed through an area of bronchial 
epithelial high grade dysplasia or carcinoma in situ, especially 
at station 7 (20). Considering that all other nodes were benign, 
the possibility of contamination during EBUS-TBNA seems low. 
Other possible explanation of the positive result of station 7 from 
EBUS-TBNA is that mediastinoscopy result was false negative (5).
  There are some limitations to our study. First, we did not per-
form ROSE. Some studies have suggested that ROSE may im-
prove the diagnostic performance of TBNA in evaluating of 
lymphadenopathy (22, 23). However, other recent studies have 
shown that ROSE does not affect diagnostic performance, but 
only allows for avoidance of unnecessary biopsies and reduces 
the complication rate (24, 25). Moreover, a recent study reported 
some cases of discrepancy between the ROSE and final diagnosis 
of EBUS-TBNA (26). Thus, considering that we obtained tissue 
cores in 95.1%, the use of ROSE would have had little influence 
in our study. Second, relatively large numbers (147 nodes) were 
excluded from the analysis because in this retrospective study, 
not all patients received surgical sampling for benign lymph 
nodes from EBUS-TBNA. Finally, most lymph nodes with posi-
tive EBUS-TBNA results were not subsequently confirmed by 
surgical sampling because of known high positive predictive 
value of EBUS-TBNA (5, 7) and the risk of surgical sampling. Thus, 
an accurate false positive EBUS-TBNA result could not be eval-
uated.
  In conclusion, bronchoscopists should consider the impact 
of nodal stations on diagnostic performances of EBUS-TBNA. 
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